Clinical TrialJul 16, 2026, 09:32 AM
Clearmind Medicine's intranasal MEAI shows improved nasal retention
AI Summary
Clearmind Medicine Inc. announced compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI, a treatment for Alcohol Use Disorder (AUD). The study demonstrated markedly improved nasal residence characteristics compared to a standard MEAI solution, which is crucial for maximizing drug absorption and therapeutic potential. These findings reinforce Clearmind's strategy to develop differentiated, next-generation treatments and validate its nasal drug-delivery platform.
Key Highlights
- Intranasal MEAI formulation demonstrated markedly improved nasal residence characteristics.
- Ex vivo study on rabbit nasal mucosa showed clear retention advantage over standard MEAI solution.
- Mucoadhesive polymer system in the formulation contributed to enhanced retention.
- Extended nasal residence time is critical for maximizing MEAI absorption and therapeutic potential.
- Results validate Clearmind's nasal drug-delivery platform for improved performance.
Price Impact
More from CMND